Immunogenicity

This two day event is designed to enhance SMis portfolio of pharmaceutical conferences, especially with a growing demand for biologic therapeutics.

We ask the questions: What stimulates an immune response? How does the system cope with immunogenic compounds? And how do you screen for potential problems?

The Conference will address all these concerns and enable Clinical Immunologists, Physicians and Specialists within the field of Immunogenicity to discuss the major challenges currently being faced within the pharmaceutical industry.

The focus is on pre-clinical analysis and assessing treatments for clinical development. It will endeavour to look at the assessment of early risks in immunogenicity and the evaluation of in silico tools for determining immunogenicity. With an insight into the safety, development and validation of Monoclonal Antibodies.

From a clinical perspective, the conference will assess consideration and design of biologic therapeutics, clinical implications and review what the clinical outcomes are from using these immune modulatory approaches.

The conference will also look at, how to benefit the patient by assessing efficacy and toxicological concerns alongside the management of immunogenic responses. With regulators supposing that animal studies are not good predictors – how can predictability be shown with pre-clinical in-vitro tools?

Business Benefits:
-Grasp an understanding of Immunogenicity and gain an insight into assessing early risks
-Hear case studies on the tools for consideration being utilised for the determination of immunogenicity
-Assess major hurdles in clinical development and the implications in design of biologic therapeutics
-Enhance your understanding on how to best evaluate read outs for immune response